Publication: Development of a lead inhibitor for the A16V+S108T mutant of dihydrofolate reductase from the cycloguanil-resistant strain (T9/94) of Plasmodium falciparum
Issued Date
2000-07-13
Resource Type
ISSN
00222623
Other identifier(s)
2-s2.0-0034644146
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Medicinal Chemistry. Vol.43, No.14 (2000), 2738-2744
Suggested Citation
Yongyuth Yuthavong, Tirayut Vilaivan, Netnapa Chareonsethakul, Sumalee Kamchonwongpaisan, Worachart Sirawaraporn, Rachel Quarrell, Gordon Lowe Development of a lead inhibitor for the A16V+S108T mutant of dihydrofolate reductase from the cycloguanil-resistant strain (T9/94) of Plasmodium falciparum. Journal of Medicinal Chemistry. Vol.43, No.14 (2000), 2738-2744. doi:10.1021/jm0009181 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/25862
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Development of a lead inhibitor for the A16V+S108T mutant of dihydrofolate reductase from the cycloguanil-resistant strain (T9/94) of Plasmodium falciparum
Abstract
The Ala16Val+Ser108Thr (A16V+S108T) mutant of the Plasmodium falciparum dihydrofolate reductase (DHFR) is a key mutant responsible for cycloguanil-resistant malaria due to steric interaction between Val-16 and one of the C-2 methyl groups of cycloguanil. 4,6-Diamino-1,2-dihydrotriazines have been prepared, in which both methyl groups of cycloguanil are replaced by H or by H and an alkyl or phenyl group, and their inhibition constants against wild-type and mutant DHFR determined. The S108T mutation is considered to decrease cycloguanil binding further through the effect on the orientation of the p-chlorophenyl group. By moving the p-chloro-substituent to the m-position in the chlorophenyl group, the activity against the A16V+S108T mutant enzyme is improved, and this effect is reinforced by the p-chloro substituent in the 3,4-dichlorophenyl group. A lead compound has been found with inhibitory activity similar to that of cycloguanil against the wild-type DHFR and about 120-fold more effective than cycloguanil against the A16V+S108T mutant enzyme. The activity of this compound against P. falciparum clone (T9/94 RC17) which harbors the A16V+S108T DHFR is about 85-fold greater than cycloguanil.